Pamicell Confirms Superiority of Intravenous Administration of Allogeneic Stem Cell Therapy

[Asia Economy Reporter Hyungsoo Park] Pamisel announced on the 16th that a paper confirming the effective administration route of ‘Cellgram-CKD’ in a chronic kidney disease animal model was published in the international journal International Journal of Stem Cells.

The research was conducted jointly with the Seoul Asan Medical Center research team. In the animal model, different cell dosages were administered via intravenous and renal artery injection methods. The creatinine clearance rate, which measures how much creatinine?a waste product produced in muscles?is filtered by the kidneys, and blood urea nitrogen levels, which test nitrogen from urea in the blood, were compared.

Observations were made for up to 24 weeks. According to the paper, when a high dose was administered intravenously, the creatinine clearance rate showed significantly higher values. Blood urea nitrogen levels showed lower values compared to the control group, confirming potential efficacy. The injection method was found to be relatively easy and minimally invasive.

Cellgram-CKD can be administered intravenously, making the procedure easier compared to Hearticellgram-AMI, which is administered through the coronary artery, and Cellgram-LC, which is injected via the hepatic artery. Cellgram-CKD is an allogeneic stem cell therapy using stem cells from healthy donors, eliminating the need to harvest bone marrow from patients, thereby reducing patient burden.

A Pamisel official stated, "Allogeneic stem cell therapies are expected to have high marketability as they not only provide consistent therapeutic effects but are also easy to administer to patients," adding, "Phase 1 clinical trials of Cellgram-CKD are progressing smoothly at Seoul Asan Medical Center, and patient recruitment is in its final stages."

The Phase 1 clinical trial of Cellgram-CKD is being conducted as part of an advanced medical technology development project supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.

This content was produced with the assistance of AI translation services.